Back to News
Market Impact: 0.25
Sobi and Innate announce partnership is now effective following completion of closing conditions
Source: PR Newswire
Healthcare & BiotechM&A & Restructuring
Swedish Orphan Biovitrum (Sobi) and Innate Pharma announced that their previously disclosed strategic partnership became effective on Sept. 16, 2026. The notice confirms completion of the partnership’s effectiveness condition but provides no financial terms, program details, or expected revenue impact.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.25
Ticker Sentiment
IPHA0.65
SOBI0.40
More News
- California AG Says Paramount-WBD Merger Would Hurt the State
- California AG Bonta on Paramount-Warner Bros., Meta and AI
- Jana Partners pushes Cooper to replace CEO, weigh asset sales- WSJ
- Lucid et Bolt s'associent pour développer et déployer à grande échelle des solutions de mobilité autonome en Europe
- Halozyme prices $1.3 billion convertible notes offering
- Paramount is getting an assist from a key California pol as it defends its Warner merger against AG Rob Bonta
From AllMind Research
- Anthropic IPO Preview: Valuation, Timing, and What to Watch
- Shein After the IPO: Venue, Valuation, and What Must Be Proved
- What AI Research Tools Should a Small Hedge Fund Buy First?
- How to Track Guidance Changes Across a Coverage List With AI
- Stop Treating AI Like a Chatbot: What Are Agents, SubAgents, MCP, and Skills, and How Do They Actually Work?